Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)

Study:

A 28 Week, Treatment Randomized, Double -Blind, Placebo-controlled Study of the Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)

Rationale:

n/a

Purpose:

The purpose of this study is to see whether a new investigational drug (Imatinib) may help improve asthma in people whose symptoms are not well controlled with high dose inhaled corticosteroid treatment.

Study Status: Recruiting

Recruiting:
Jackie Sharp pylej@ccf.org

Condition Intervention Phase
Asthma Drug: Imatinib mesylate
Drug: Placebo
Phase 2

Verified by Brigham and Women`s Hospital July, 2013

Sponsored by: Brigham and Women`s Hospital
Information provided by: Brigham and Women`s Hospital
ClinicalTrials.gov identifier: NCT01097694

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Elliot Israel, M.D., Principal Investigator
Joshua Boyce, M.D., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site